Hepatocellular carcinoma treated with transarterial chemoembolization: Dynamic perfusion-CT in the assessment of residual tumor

被引:14
|
作者
Davide Ippolito [1 ,2 ]
Pietro Andrea Bonaff ini [1 ,2 ]
Laura Ratti [3 ]
Laura Antolini [1 ,2 ]
Rocco Corso [4 ]
Ferruccio Fazio [1 ]
Sandro Sironi [1 ,2 ]
机构
[1] Department of Diagnostic Radiology, School of Medicine, University of Milano-Bicocca,H S. Gerardo
[2] Department of Clinical Medicine Prevention and Biotechnology, Section of Medical Statistics, H S. Gerardo
[3] Department of Clinical Medicine, School of Medicine, University of Milano-Bicocca, H S. Gerardo
[4] Department of Interventional Radiology, H S. Gerardo
关键词
Computed tomography-perfusion; Functional-computed tomography; Hepatocellular carcinoma; Trans-arterial chemoembolization; Tumour neo-angiogenesis;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
AIM: To asses the value of computed tomography (CT)-perfusion in the detection of residual hepatocellular carcinoma (HCC) vascularization after transarterial chemoembolization (TACE). METHODS: Thirty-two consecutive patients were pro-spectively included in this study. All patients had liver cirrhosis and a conf irmed HCC lesion which was treated with TACE. One month after treatment, perfusion measurements of treated lesions were carried out. The CTperfusion (CT-p) protocol was performed with 16 slice multidetector computed tomography which included the following parameters: 8 dynamic slices/scan per 40 scans after iv injection of 50 mL of iodinated contrast (350 mg/mL) at a flow rate of 6 mL/s. Treated lesions were evaluated using dedicated perfusion software, which generated a quantitative colour map of perfusion. The following parameters were considered: hepatic perfusion (HP), arterial perfusion (AP), blood volume (BV), hepatic perfusion index (HPI), and time to peak (TTP). Perfusion parameters were described with quartile values of their distribution and statistically analyzed. RESULTS: Perfusion parameters of the treated lesions could be quantitatively assessed using CT-p analysis. The presence of residual tumor tissue was observed in 13 of the 32 patients. The values of the perfusion parameters measured within the relapse tissue were: HP (mL/100 g per minute): median = 44.4 (1stqt = 31.3, 3rdqt = 55.8); BV (mL/100 g): median = 18.7 (1stqt = 11.5, 3rdqt = 22.5); AP (mL/min): median = 39.0 (1stqt = 36.5, 3rdqt = 61.3); HPI (%): median = 34.0 (1stqt = 30.4, 3rdqt = 38.9); TTP (s): median = 17.3 (1stqt = 15.8, 3rdqt = 26.5). With the use of the univariate paired Wilcoxon signed rank test, HP, AP and HPI were shown to be significantly higher (P<0.001) in the relapse site than in the primary lesion. The BV and TTP parameters showed a tendency to be greater and lower, respectively, in the relapse site than in the primary lesion. CONCLUSION: In patients with HCC treated with TACE, CT-p provides measurement of flow parameters related to residual arterial structures in viable tumor, thus helping in the assessment of therapeutic response.
引用
收藏
页码:5993 / 6000
页数:8
相关论文
共 50 条
  • [41] MDCT Versus MRI Assessment of Tumor Response After Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
    Kloeckner, Roman
    Otto, Gerd
    Biesterfeld, Stefan
    Oberholzer, Katja
    Dueber, Christoph
    Pitton, Michael B.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2010, 33 (03) : 532 - 540
  • [42] Hepatocellular carcinoma under transarterial chemoembolization
    Vogl, TJ
    Trapp, ME
    Schroeder, HF
    Haupt, G
    Pegius, W
    Mack, MG
    RADIOLOGY, 1997, 205 : 65 - 65
  • [43] Preresection transarterial chemoembolization for hepatocellular carcinoma
    Tin, Sim
    Wiwanitkit, Viroj
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2015, 34 (02) : 188 - 188
  • [44] Transarterial percutaneous Chemoembolization in Hepatocellular Carcinoma
    Petersen, Johannes
    Henninger, Benjamin
    Glodny, Bernhard
    Jaschke, Werner
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2013, 163 (5-6) : 123 - 127
  • [45] γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
    Guo, Jianhai
    Liu, Shaoxing
    Gao, Song
    Kou, Fuxin
    Zhang, Xin
    Liu, Peng
    Yang, Renjie
    Zhu, Xu
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2021, 32 (03) : 419 - +
  • [46] The prognostic value of radiomics for hepatocellular carcinoma treated with transarterial chemoembolization(TACE)
    Li Guiyu
    Ma Wenhui
    Jing Wang
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [47] Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma
    Chen, Guang
    Ma, Da-Qing
    He, Wen
    Zhang, Bao-Feng
    Zhao, Li-Qin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (37) : 5738 - 5743
  • [48] Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization
    Kassab, Ihab
    Singal, Amit G.
    Ali, Aamir
    Narasimman, Manasa
    Arvind, Ashwini
    Ahmed, Muneeb
    Joshi, Sagar
    Manzoor, Komal
    Rich, Nicole
    Chen, Vincent L.
    Zhao, Zhe
    Sarwar, Ammar
    Parikh, Neehar D.
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (04)
  • [49] NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization
    Adhoute, Xavier
    Penaranda, Guillaume
    Raoul, Jean Luc
    Bollon, Emilie
    Pol, Bernard
    Letreut, Yves P.
    Perrier, Herve
    Bayle, Olivier
    Monnet, Olivier
    Beaurain, Patrick
    Muller, Cyril
    Hardwigsen, Jean
    Lefolgoc, Gaelle
    Castellani, Paul
    Bronowicki, Jean P.
    Bourliere, Marc
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (06) : 706 - 715